Shenyi Technology Reports Commercialization of Brain-Computer Interfaces, With Three Product Lines for Sleep and Depression

leaderobot.com reported on September 21, 2026, that Shenyi Technology is advancing the commercialization of products for brain function monitoring and intervention.

If the report is accurate, the important point is that the company is seeking to commercialize brain-computer interfaces for specific applications—sleep, depression and deep neuromodulation—rather than keeping them at the research stage. Medical applications require preclinical validation and registration, while consumer products must be compact and suitable for continued use, so the requirements differ even for the same technology.

What is new in this report on Shenyi Technology is that its commercialization plan, which integrates the measurement, understanding and intervention of brain function, is organized into three product lines: sleep, depression and noninvasive deep neuromodulation. However, this is not primary information demonstrating the technology’s merits; it is material at the stage where a media outlet has reported executives’ explanations. For now, the key issue is how to connect research and development to preclinical validation, registration, preparations for mass production and actual use.\n\nThis newspaper has no related coverage, so we will not connect this report to past coverage. The issue it raises, however, is the idea of moving brain-computer interfaces from “papers and one-off technological breakthroughs” to “product portfolios for specific scenarios.” The three layers—portable devices for sleep, home-based treatment for depression, and deep neuromodulation—represent a structure in which the same technology platform is directed toward different applications. The focus, therefore, is less on the performance of a single product than on how measurement data are interpreted and linked to intervention. See the original source for details.\n\nFrom an industry-structure perspective, the challenge is not limited to miniaturizing hardware. According to the report, the key questions are whether the algorithms can move from population models to individual models, and whether the technology can be developed to meet the requirements of preclinical validation and registration for medical applications. For noninvasive deep neuromodulation, the question is how it differs from conventional approaches targeting the cortex. However, it is said to be at the animal-testing and IIT-trial stages, so assessment of its implementation will come later. Going forward, it will be important to track which of the three product lines is commercialized first, the timing of prototyping and mass production, progress related to clinical trials, and the scope of indications each product is targeting.